Adjunctive Effects of Psilocybin and Buprenorphine
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
Primary Aim: In participants with OUD in early or sustained full recovery on
buprenorphine/naloxone therapy, to characterize adverse events associated with adding two
psilocybin doses to a stable buprenorphine/naloxone regimen.
Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of
buprenorphine/naloxone maintenance therapy.
Secondary Aim: To evaluate the effect of concurrent buprenorphine/naloxone use on the effects
of psilocybin therapy.
Descriptive Aim: To describe any changes in self-efficacy, quality of life, pain.